Related Experiment Video
Updated: Jun 6, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
The safety of clopidogrel
Kiran Kumar R Mangalpally1, Neal S Kleiman
1Sparrow Hospital, Michigan State University, Lansing, USA.
Insights
Clopidogrel, an antiplatelet drug, is linked to bleeding risks. While generally safer than aspirin alone, higher doses and combination therapy increase bleeding, necessitating a risk-benefit assessment.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Clopidogrel is a vital antiplatelet prodrug for acute coronary syndromes and post-stent placement.
- Bleeding is a significant adverse effect of clopidogrel, potentially leading to treatment noncompliance.
Purpose of the Study:
- To review the safety profile of clopidogrel, including various dosing strategies and combinations.
- To assess the bleeding risks associated with clopidogrel monotherapy versus combination antiplatelet therapy.
Main Methods:
- Literature search of randomized controlled trials in Medline.
- Review of clopidogrel's mechanism of action, dosing, and safety in different clinical contexts.
- Examination of thrombotic thrombocytopenic purpura as a rare adverse event.
Main Results:
- Clinicians can better understand the safety of different clopidogrel loading doses.
- The incidence of bleeding with clopidogrel, alone or with other agents, is clarified.
Conclusions:
- Clopidogrel monotherapy results in less severe bleeding and intracranial hemorrhage compared to aspirin.
- Increased bleeding risk is associated with higher clopidogrel loading doses and combination therapy.
- Balancing bleeding risks against therapeutic benefits is crucial when using clopidogrel, especially with other antiplatelet agents.
Importance Of The Field:
Clopidogrel is an antiplatelet prodrug widely used in acute coronary syndromes and after intravascular stent placement. Acute or chronic use can cause bleeding, a major adverse effect, which can lead to drug discontinuation or noncompliance with therapy.
Areas Covered In This Review:
The mechanism of action of clopidogrel, safety of different loading doses of clopidogrel, its use as a solitary antiplatelet agent and concomitant use with other antiplatelet agents such as aspirin and warfarin are discussed. Thrombotic thrombocytopenic purpura, a rare but important adverse event, has also been reviewed. Literature searches including randomized controlled trials were conducted in Medline.
What The Reader Will Gain:
Clinicians will be able to understand the safety profile of using different doses of clopidogrel and the incidence of bleeding when used alone or in combination with other antiplatelet agents.
Take Home Message:
Compared to aspirin, clopidogrel when taken alone causes less severe bleeding and less intracranial hemorrhage. Higher loading dose of clopidogrel is associated with increased bleeding. When combined with other antiplatelet agents, risk of bleeding increases, but like any other drug, the risks have to be weighed against potential benefits.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Coronary Artery Disease V: Interprofessional Care